Pharmacokinetics Clinical Trial
This is a comparative pharmacokinetic, pharmacodynamic and safety study in healthy volunteers with three forms of pegylated granulocyte colony stimulating factors.
Status | Recruiting |
Enrollment | 192 |
Est. completion date | September 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male and female subjects aged 18 to 55 years 2. A standardized body mass index 3. General good health as determined by the Investigator 4. Normal organ function as per the Investigator's judgement 5. Must be non-smokers, or ex-smokers who have not smoked within the previous 6 months from the screening visit 6. Female subjects must: - Not be lactating; not be pregnant - Agree to use an acceptable contraceptive method or be of non-childbearing potential 7. Male subjects must refrain from donating sperm or fathering a child during the study and until 3 months after the last study drug Exclusion Criteria: 1. Known hypersensitivity to Escherichia coli derived proteins, pegfilgrastim, filgrastim or any other related component 2. Presence of antibodies to polyethylene glycol at screening 3. Positive result for cotinine (>500 ng/mL) or drugs of abuse at screening or on admission 4. Prior history of or current alcohol abuse or excessive intake of alcohol as judged by the Investigator 5. Donation of blood (=500 mL) or plasma within the previous 3 months 6. History of unexplained syncopal episodes; 7. Any disorder that, in the Investigator's opinion, may interfere with study compliance 8. History of any cancer 9. History of pulmonary infiltrate or pneumonia within the previous 6 months from screening visit 10. Hereditary fructose and/or sorbitol intolerance 11. Absolute neutrophil count below 1500/mm3 or above 12000/mm3 at screening 12. Positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) 1 or 2 13. Any abnormality in 12-lead ECG that in the Investigator's opinion is clinically significant and/or suggestive of underlying cardiac abnormalities 14. A clinical diagnosis of hypertension, significant hypercholesterolemia as judged by the Investigator, or thyroid abnormalities 15. Family history of acute myeloid leukemia or subjects with splenomegaly at baseline, or with sickle cell disease 16. Any prescribed or over the counter medications including analgesics, herbal remedies, vitamin therapy must not be used from 7 days prior to the first administration of study drugs |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | QPS Bio-Kinetic | Springfield | Missouri |
Lead Sponsor | Collaborator |
---|---|
Dr. Reddy's Laboratories Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax | Maximum plasma concentration | 105 days | No |
Primary | AUC(0-inf) | Area under concentration-time curve extrapolated from time 0 to infinity | 105 days | No |
Primary | AUC(0-t) | Area under concentration-time curve from time 0 to the time of the last quantifiable concentration | 105 days | No |
Primary | Emax | Maximum observed effect | 105 days | No |
Primary | AUEC(0-t) | Area under the effect time curve from time zero (predose) to last measured time | 105 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04092725 -
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04181008 -
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers
|
Early Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT04406415 -
Oral Nafamostat in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
Completed |
NCT02534753 -
A Pharmacokinetics Study of Intravenous Ascorbic Acid
|
Phase 1 | |
Completed |
NCT01682408 -
Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability
|
Phase 1 | |
Completed |
NCT01976078 -
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
|
N/A | |
Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
Completed |
NCT01214941 -
Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
|
Phase 4 | |
Completed |
NCT01260025 -
Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor
|
Phase 1 | |
Completed |
NCT00746499 -
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
|
Phase 1 | |
Completed |
NCT01276119 -
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
|
Phase 1 | |
Completed |
NCT00747721 -
Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU
|
Phase 1 | |
Completed |
NCT00856570 -
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 | |
Completed |
NCT01055964 -
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
|
Phase 3 | |
Completed |
NCT00983242 -
Drug-Drug Interaction Between Colchicine and Verapamil ER
|
Phase 1 |